FDA Clears First Generic Baloxavir for Influenza Treatment, Postexposure Prophylaxis

The FDA has approved the first generic version of baloxavir marboxil tablets (Xofluza), a single-dose antiviral option for treatment of acute uncomplicated influenza and postexposure prophylaxis in patients aged 5 years or older. The approval, granted to Norwich Pharmaceuticals, Inc, comes ahead of the 2026-2027 influenza season and may broaden access to an antiviral used in both otherwise healthy patients and those at increased risk for influenza-related complications.¹

“Today’s approval marks a meaningful milestone for the treatment of influenza,” Iilun Murphy, MD, director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research, said in the June 17, 2026, FDA announcement. “Expanding patient access to drugs and improving their ease of use are critical public health imperatives, particularly given that influenza alone accounts for millions of illnesses in the U.S. each year.”¹

The generic product is indicated for treatment of acute uncomplicated influenza in patients aged 5 years or older who have been symptomatic for no more than 48 hours and are either otherwise healthy or at high risk for complications. It is also indicated for postexposure prophylaxis after contact with an individual with influenza in the same age group.¹ The FDA announcement did not report new clinical efficacy data; generic approvals generally rely on demonstration that the generic product meets applicable regulatory standards for equivalence to the reference listed drug.

Baloxavir marboxil is an oral prodrug of baloxavir acid, a selective inhibitor of the influenza virus cap-dependent endonuclease, an enzyme required for viral messenger RNA synthesis. This mechanism distinguishes it from neuraminidase inhibitors such as oseltamivir, zanamivir, and peramivir, which act later in the viral replication cycle by blocking virion release.²

Clinical evidence supporting baloxavir’s reference product includes randomized trial data in uncomplicated influenza. In CAPSTONE-1, a phase 3 trial in otherwise healthy adolescents and adults, single-dose baloxavir shortened time to alleviation of symptoms compared with placebo and reduced viral load more rapidly than oseltamivir, although symptom improvement was similar between the baloxavir and oseltamivir groups.² In CAPSTONE-2, conducted among outpatients at high risk for influenza complications, baloxavir reduced time to improvement of influenza symptoms compared with placebo and showed similar overall symptom outcomes to oseltamivir, with some differences by influenza virus subtype reported by investigators.³

For postexposure prophylaxis, a randomized household-contact trial found that baloxavir reduced laboratory-confirmed clinical influenza compared with placebo among contacts of index patients with influenza.⁴ These data helped establish baloxavir as an option not only for early treatment but also for prevention after exposure, a use case that may be relevant in households with high-risk individuals or during institutional outbreaks, depending on local protocols and susceptibility patterns.

The prescribing information for the generic product includes the same contraindications, warnings, and precautions as Xofluza, according to the FDA. Baloxavir marboxil is contraindicated in patients with a known history of hypersensitivity to baloxavir marboxil or any tablet ingredient. The FDA also noted warnings related to increased incidence of treatment-emergent resistance in patients younger than 5 years, an age group for which this generic approval does not apply.¹

The most common adverse events listed in the FDA announcement were diarrhea, bronchitis, nausea, sinusitis, and headache.¹ In clinical practice, safety considerations also include the potential for antiviral resistance, particularly polymerase acidic protein substitutions associated with reduced baloxavir susceptibility that were observed in clinical development.²,³

For clinicians, the practical implication of the approval is less a change in the antiviral evidence base than a potential change in availability and cost. A single-dose oral regimen may be useful when adherence to a multidose neuraminidase inhibitor is a concern, but treatment decisions still depend on timing of symptom onset, patient risk factors, circulating influenza activity, local resistance considerations, drug access, and contraindications.

The approval does not expand baloxavir use beyond the established age and indication limits. Key unanswered questions for clinicians include real-world uptake of the generic product, comparative affordability at the pharmacy level, and ongoing surveillance for resistance as use increases across treatment and prophylaxis settings.

References

1. US Food and Drug Administration. FDA approves first single-dose generic treatment for influenza. News release. Published June 18, 2026. Accessed July 7, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-single-dose-generic-treatment-influenza
2. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913-923. doi:10.1056/NEJMoa1716197
3. Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza: a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10):1204-1214. doi:10.1016/S1473-3099(20)30004-9
4. Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020;383(4):309-320. doi:10.1056/NEJMoa1915341